CGI Pharmaceuticals (formerly Cellular Genomics) is using a chemical genetics platform to discover and develop new therapies for cancer and inflammatory diseases. The company also helps other drug makers fill their pipelines with the help of its chemical genetics screening technology. Its specialty is identifying and developing kinase inhibitor therapeutics, but it also offers assay development, in vivo disease modeling, and clinical and regulatory affairs management. Partners include Pfizer, Merck Serono, and Eli Lilly.

Champions Biotechnology, Inc. company was founded in 1985 and is based in Baltimore, Maryland. Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies.Champions Biotechnology provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patients cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patient's. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial.Chelsea Therapeutics company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus.

ChemGenex Pharmaceuticals is looking for treatments that are tailor-made for different patients. The company is researching targeted cancer therapies, finding genetic differences that affect how well patients respond to certain drugs and tailoring therapies accordingly. Its lead candidate is omacetaxine mepesuccinate (formerly called Ceflatonin); the drug is undergoing clinical testing as a treatment for chronic myeloid leukemia in patients who have a genetic mutation that makes them resistant to Novartis' Gleevec. Also in clinical development is Quinamed, a potential tumor fighter. The company has several other preclinical oncology programs as well.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.